Prelude Therapeutics Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. The company is a clinical-stage oncology biopharmaceutical company with no product revenue and no approved products.
Financial results and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $21.3m | $22.4m | $44.1m | $38.9m |
| General and administrative expense | $8.2m | $5.5m | $15.6m | $11.0m |
| Total operating expenses | $29.5m | $27.9m | $59.7m | $49.9m |
| Net loss | $27.4m | $26.9m | $56.8m | $48.2m |
| Net loss per share, basic and diluted | $0.58 | $0.58 | $1.20 | $1.06 |
- Cash and liquidity: Cash, cash equivalents and marketable securities totaled $246.3m at June 30, 2022; restricted cash of $4.0m was additional. Management expected available cash and securities to fund operating and capital needs into the second half of 2024, subject to assumptions and spending risks.
- Cash flow: Six-month operating cash use was $40.4m, versus $36.1m in 2021. Investing activities provided $58.7m, largely reflecting maturities of marketable securities, while financing provided $0.5m. Cash, cash equivalents and restricted cash ended the period at $54.8m.
- Assets, liabilities and debt: Total assets were $259.1m and total liabilities $18.2m. The filing reports no credit facility or committed capital source; it does not identify funded debt. Lease liabilities were $1.8m at June 30.
- Margins: Not meaningful because the company had no revenue. Accumulated deficit was $276.0m.
Material changes versus prior comparable periods
- Q2 operating expenses increased $1.5m and net loss increased $0.5m year over year. R&D expense fell $1.1m, primarily following the PRT543 clinical-development wind-down as the company concentrated PRMT5 development efforts on PRT811. G&A rose $2.6m, reflecting higher stock-based compensation, headcount and professional fees.
- For the first half, operating expenses rose $9.9m and net loss increased $8.7m year over year. R&D increased $5.3m with discovery-stage spending and pipeline advancement; G&A increased $4.6m. Other income increased to $2.9m from $1.7m, principally from Delaware research and development tax credits and interest income.
- Available-for-sale securities had a $1.6m unrealized loss in the first half, recorded in other comprehensive loss. Marketable securities declined to $195.6m from $259.4m at year-end, while cash and cash equivalents increased to $50.7m from $31.8m.
Outlook, operations and risks
- Pipeline plans: PRT811 was prioritized for biomarker-selected populations based on reported safety, target engagement and brain-penetration characteristics. Management planned to analyze PRMT5 expansion-cohort data and report next steps in the second half of 2022. The IV formulation of PRT1419 was prioritized; PRT2527 dose-escalation enrollment and a recommended Phase 2 dose were targeted for the second half of 2022. PRT3645 trial initiation and a SMARCA2 degrader IND submission were targeted by year-end 2022.
- Spending and financing: Management expected significant R&D and G&A spending and operating losses to continue. The company may seek equity or debt financing, collaborations, strategic alliances or licensing arrangements; financing may be unavailable or dilute shareholders or require concessions.
- Facility commitment: An August 2022 amendment to the planned Chestnut Run office and laboratory lease increased base rent over its initial 162-month term to approximately $42.6m. The lease covers approximately 81,000 rentable square feet and commencement depends on completion of landlord work or the company taking possession. Estimated rent payments begin in 2024; the lease obligation was not included in June 30 balance-sheet lease liabilities.
- Grant contingency: The company received $2.4m from Delaware for lab-space development, deferred as a liability pending recognition over the related assets’ useful lives. Repayment may be required if eligible costs fall short or the company leaves Delaware within five years. A separate $0.3m performance-benchmark payment was recognized as other income; shortfalls against employment benchmarks may also require repayment.
- Key risks: Clinical efficacy and safety remain unproven, and clinical trials may be delayed by enrollment, competition, COVID-19 or third-party CRO/CMO supply and execution issues. The company also cited substantial competition, intellectual-property and regulatory risks, inflation-related cost pressure, and the need for additional capital. COVID-19 had caused limited site-initiation, participation and enrollment delays, though lead programs and research were described as on track.
- Other disclosures: Management reported effective disclosure controls at a reasonable-assurance level and no material quarterly change in internal control over financial reporting. The company reported no material pending legal proceedings.
Important facts for investors to verify
- Whether the stated cash runway into the second half of 2024 remains achievable as clinical, personnel and facility spending develops.
- Subsequent clinical data and actual progress against the stated 2022 milestones for PRT811, PRT1419, PRT2527, PRT3645 and the SMARCA2 program.
- Lease commencement timing, total expected occupancy costs and any resulting balance-sheet lease liability once recognized.
- Compliance with Delaware grant employment and lab-cost conditions, including potential repayment obligations.
- Whether additional financing, clinical setbacks, competition or supply constraints change program priorities, spending or dilution risk.